Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), is a biopharmaceutical company that acquires, develops and commercializes a diversified portfolio of oncology and other drug candidates that meet critical health challenges for which there are few other treatment options.
The information here can be found on the company website:
Spectrum’s expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The Company’s pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.
Spectrum’s passion to identify, develop and deliver better options for people suffering from cancer is behind every action they take. At Spectrum, everyone is committed to excellence and strives to make a difference every day.
The Company’s lead drug, Satraplatin, is a Phase 3 oral, anti-cancer drug being codeveloped with GPC Biotech AG for its initial indication – second-line chemotherapy for hormone-refractory prostate cancer – and has been granted fast-track status by the FDA. In March, Spectrum announced the pending acquisition of Isovorin™ (LFA), potentially useful in the treatment of colorectal and bone cancer. A new drug application (NDA) for LFA has been filed with the FDA and LFA has two orphan drug designations.
Spectrum also has four products in five Phase 2 trials: Elsamitrucin, which will initially target non-Hodgkin’s lymphoma; EOquin®, a synthetic prodrug that is being studied in the treatment of superficial bladder cancer; Ozarelix, for the treatment of prostate cancer and benign prostatic hypertrophy; and Lucanthone, a radiation sensitizer in the treatment of cancer. Other drugs in development include RenaZorb™, used in the treatment of end stage renal disease, SPI-1620, an adjunct to chemotherapy, and SPI-205 for chemotherapy induced neuropathy.
Additionally, in order to generate near-term revenue, Spectrum is building a generic drug portfolio. The Company’s current collection of generic drugs covers multiple platforms, including injectable and ophthalmic products. In February 2006, Spectrum entered a strategic alliance with Par Pharmaceutical Companies, Inc. for the sale and distribution of current and future generic drugs developed by Spectrum.
To date, Spectrum has filed thirteen Abbreviated New Drug Applications (ANDA) and received final regulatory approval for three drugs, ciprofloxacin tablets, carboplatin “ready-to-use” liquid injection, and fluconazole tablets.
Spectrum Pharmaceuticals is led by Dr. Rajesh Shrotriya, President and Chief Executive Officer.
For more information about Spectrum Pharmaceuticals, please visit their website.
